MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
1.510
+0.030
+2.03%
After Hours: 1.510 0 0.00% 17:01 03/21 EDT
OPEN
1.470
PREV CLOSE
1.480
HIGH
1.530
LOW
1.470
VOLUME
683.19K
TURNOVER
--
52 WEEK HIGH
12.85
52 WEEK LOW
0.8700
MARKET CAP
48.35M
P/E (TTM)
-0.2844
1D
5D
1M
3M
1Y
5Y
1D
Outlook Therapeutics files to sell 21.72M shares of common stock for holders
TipRanks · 2d ago
OUTLOOK THERAPEUTICS FILES PROSPECTUS COVERING OFFER & RESALE BY SELLING STOCKHOLDERS OF UP TO 21.7 MLN SHARES OF COMMON STOCK- SEC FILING
Reuters · 2d ago
Outlook Therapeutics management to meet virtually with BTIG
TipRanks · 2d ago
Weekly Report: what happened at OTLK last week (0310-0314)?
Weekly Report · 5d ago
Weekly Report: what happened at OTLK last week (0303-0307)?
Weekly Report · 03/10 12:24
Weekly Report: what happened at OTLK last week (0224-0228)?
Weekly Report · 03/03 12:22
Based on the provided financial report, the title of the article is: "OUTLOOK THERAPEUTICS, INC. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2024
Press release · 03/02 05:11
Outlook Therapeutics files to sell 7.07M shares of common stock for holders
TipRanks · 02/28 21:40
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.